Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01) - Neelima Denduluri; Seock-Ah Im; Yoshinori Ito; Javier Cortes; Keun Seok Lee; Ian E. Krop; Hiroji Iwata; Sung-Bae Kim; Kenji Tamura; Antoine Yver; Sara A. Hurvitz; Caleb Lee; et al. (Cancer Research, 2020)